

## R&D Pipeline

antibody  
 protein  
 small molecule  
 © New Molecular Entity  
 Updated since Dec. 31, 2019  
 Updated since Mar 31, 2020

### Nephrology

As of Jun. 30, 2020

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Hemodialysis)	CN						[Kirin-Amgen]
KHK7580 Evocalcet Oral	Calcimimetic	Secondary Hyperparathyroidism	CN KR TW HK						[Mitsubishi Tanabe Pharma]
© RTA 402 Bardoxolone Methyl Oral	Antioxidant Inflammation Modulator	Diabetic Kidney Disease	JP						[Reata]
KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Preeclampsia	JP						[In-House]
KHK7791 Tenapanor Oral	NHE3 Inhibitor	Hyperphosphatemia Under Maintenance Dialysis	JP						[Ardelyx]

### Oncology

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Mycosis Fungoides and Sézary Syndrome	AU						[In-House]
© KHK2375 Entinostat Oral	HDAC Inhibitor	Adult T-cell Leukemia/ Lymphoma	US EU others						POTELLIGENT®
© KHK2455 Oral	IDO1 Inhibitor	Breast Cancer	JP						[Syndax]
KRN125 Pegfilgrastim Injection	Long-Acting Granulocyte Colony-Stimulating Factor	Mobilization of Hematopoietic stem cell into Peripheral blood Automated Injection Device for Decreasing the Incidence of Febrile Neutropenia in Patients Receiving Cancer Chemotherapy	JP						[Kirin-Amgen]
© ME-401 Oral	PI3Kδ Inhibitor	Solid Tumor	US						[In-House] Combination with KW-0761
		Urothelial carcinoma	US						[In-House] Combination with avelumab
		B-cell malignancies	JP						[MEI Pharma]
			US						
		Follicular Lymphoma	US EU AU KR others						

### Immunology/Allergy

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Axial Spondyloarthritis (axSpA)	TW						[Kirin-Amgen] Concurrent submit of an application for Psoriatic Arthritis
			JP						[Kirin-Amgen]
		Psoriasis	CN						
			MY MO						
		Systemic Sclerosis	JP						
© KHK4083 Injection	Anti-OX40 Fully Human Antibody	Palmoplantar Pustulosis	JP						[In-House] POTELLIGENT® Human Antibody-Producing Technology
© ASKP1240 Bleselumab Injection	Anti-CD40 Fully Human Antibody	Atopic Dermatitis	JP US CA EU						[In-House] Human Antibody-Producing Technology
		Recurrence of Focal Segmental Glomerulosclerosis (FSGS) in de novo kidney transplant recipients	US						Jointly Developed with Astellas

※ Since the development of KHK4083 for ulcerative colitis was suspended, clinical studies for UC were deleted from this table.

## R&D Pipeline

antibody  
 protein  
 small molecule  
 © New Molecular Entity  
 Updated since Dec. 31, 2019  
 Updated since Mar 31, 2020

Central Nervous System

As of Jun. 30, 2020

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KW-6002 Istradefylline Oral	Adenosine A <sub>2A</sub> Receptor Antagonist	Parkinson's Disease	EU						[In-House]
KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	HTLV-1 associated myelopathy (HAM)	JP						[In-House] POTELLIGENT®
©KW-6356 Oral	Adenosine A <sub>2A</sub> Receptor Antagonist	Parkinson's Disease	JP						[In-House]
©KHK6640 Injection	Anti-Amyloid Beta Peptide Antibody	Alzheimer's Disease	JP EU						[Immunas Pharma]

Other

Code Name Generic Name Formulation	Mechanism of Action	Indication	Area	Stage					[In-House or Licensed] Remarks
				Ph I	Ph II	Ph III	Filed	Approved	
KRN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH)	HK						[In-House] Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
			OM						
			CH						
			CN TW KW SA SG						
			BH						
			EU						
		US							
AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia Who Have Had an Inadequate Response to Conventional Therapy	TW						[Kirin-Amgen]
			KR						
		CN							
		JP KR TW							
KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	EU						[In-House]